A Study of TRK-950 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the safety and tolerability of TRK-950 alone
and in combination with Nivolumab in patients with advanced solid tumors